High Dose of Erythropoietin Analogue After Cardiac Arrest: a Multicentre, Randomised, Controlled Trial (Epo-ACR-02 Trial)
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Number of patients reaching a CPC (cerebral performance category) level 1 in each group
Study Overview
Brief Summary
The investigators hypothesised that the neuroprotective effects of erythropoietin and its analogues could lead to an improve outcome after cardiac arrest. To test this hypotheses, the investigators designed a randomized, multicentre, simple blind trial in which all participating patients will be receive usual treatments and 50% of them will also receive a high dose of epoetin alpha (an analogue of erythropoietin) in an "add on" fashion. The main end point will be the proportion of patients in each arm who will reach at day 60 the best level of recovery, using a 5 level score.
Detailed Description
Rationale:
A recent pilot study showed encouraging results regarding the potentially beneficial effects of high dose epoetin alpha (an analogue of erythropoietin) when administered early after cardiac arrest. In this open label and non randomized trial, a high proportion of patients survived without significant cerebral disability and without experiencing severe adverse events (CARIOU et al. Resuscitation 2008). Efficiency of this treatment should now be evaluated in a randomized trial.
Hypotheses:
An early administration of a high dose of epoetin alpha (Epo) after cardiac arrest resuscitation could improve the neurological outcome of these patients by comparison with standard treatment. The proportion of patients reaching the level 1 of the Pittsburgh CPC scale (i.e., no or minor cerebral disability) at day 60 could attain 45% in the interventional group versus 30% as expected in the control group.
Design:
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
EPO
five injections maximum of 40000 UI EPO
Intervention: EPOETINE ALPHA (Drug)
Control
Classical take care
Intervention: Control arm (Other)
Outcomes
Primary Outcomes
Number of patients reaching a CPC (cerebral performance category) level 1 in each group
Time Frame: at day 60
Secondary Outcomes
- Distribution of patients in CPC (cerebral performance category) scale(at day 30 and day 60)
- All adverse events (including thrombotic events)(until day 60)
- ICU, hospital D30 and D60 mortality(during hospitalization and at day 30 and day 60)